Glympse Bio

Glympse Bio

Glympse Bio was founded around research from the laboratories of Sangeeta Bhatia at MIT and the Wyss Institute for Biologically Inspired Engineering. The company's core technology centers on injectable nanoparticles that interact with disease-specific enzymes and release synthetic biomarkers into urine, where they are detected by a mass spectrometer. The resulting data is analyzed by proprietary algorithms to generate a disease signature. Glympse Bio initially focused on non-alcoholic steatohepatitis (NASH), a liver condition with limited non-invasive diagnostic options. The company raised $46 million in Series A financing in 2019, co-led by Andreessen Horowitz and Data Collective, with participation from Polaris Partners, Lifeforce Capital, and others. In 2021, the company announced a partnership with the National Cancer Institute to explore applications in cancer detection. The platform is designed to be programmable for multiple diseases, including fibrotic diseases and oncology, with clinical validation underway. The company maintains dual headquarters in Cambridge, Massachusetts, and San Francisco, California. Its investors include prominent venture capital firms with a focus on life sciences and artificial intelligence. Glympse Bio has published research in journals such as Nature Biomedical Engineering, demonstrating the platform's ability to distinguish between NASH and simple steatosis in animal models. The company has not publicly disclosed a CEO or executive team roster, which limits visibility into current leadership. Glympse Bio differentiates itself through its activity-based diagnostic approach, which measures real-time enzymatic activity rather than static biomarkers. This technology could enable earlier detection of disease progression and response to therapy, addressing a gap in non-invasive monitoring for chronic diseases. The platform's modular design allows it to be adapted to multiple diseases, potentially creating a pipeline of diagnostic tests.